Scancell Holdings plc (SCP.F)
Frankfurt · EUR · Healthcare · Biotechnology
€0.076 (+0.66%) as of
Key statistics
- Market cap
- 10.31M
- EPS (TTM)
- -0.2000
- Dividend yield
- 0.00%
- 52-week range
- 0.0755 – 2.9000
- Beta
- 0.69
- Profit margin
- 0.00%
- Volume
- 4.00k
About Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company offers GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling. Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oxford, United Kingdom
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.